Study to Compare different formulations of AZD3355
Study identifier:D9120C00031
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A double-blind, randomized, cross-over design, phase 1 pharmacodynamic study to investigate the effect of different formulations of AZD3355 for the development of paresthesiae after dosing in healthy subjects
Medical condition
Gastroesophageal Reflux Disease
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD3355
Sex
All
Actual Enrollment
48
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Apr 2008
Primary Completion Date: 01 Jun 2008
Study Completion Date: 01 Jun 2008
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 IR Formulation 65 mg | Drug: AZD3355 Single dose Other Name: Lesogaberan |
| Experimental: 2 IR Formulation 150 mg | Drug: AZD3355 Single dose Other Name: Lesogaberan |
| Experimental: 3 MR formulation, 1h 65 mg | Drug: AZD3355 Single dose Other Name: Lesogaberan |
| Experimental: 4 MR Formulation, 1h 150 mg | Drug: AZD3355 Single dose Other Name: Lesogaberan |
| Experimental: 5 MR Formulation, 2h 150 mg | Drug: AZD3355 Single dose Other Name: Lesogaberan |
Contacts
Investigators
Principal Investigator
Eva Ersdal
AstraZeneca R&d, Mölndal, Sweden
